SecBot SecBot
8-K ·Filed Nov 12, 2026

SKYE

Skye Bioscience, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 18h ago SEC0001628280-26-073120
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The company has no current liability from this lawsuit. Monitor for any post-trial motions or appeal filings by the plaintiff, which could reintroduce uncertainty.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.08
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.93%
T+1 · $1.09
Vs SPY
+1.29%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $1.08entry
  2. T+1 · 4d ago +0.93%α +1.29% · $1.09
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience disclosed that a jury returned a unanimous verdict in favor of the company on all claims in a whistleblower retaliation lawsuit filed by a former employee. The lawsuit sought unspecified economic and non-economic losses plus attorneys' fees. The plaintiff may file post-trial motions or appeal, but the company has no current financial exposure from this case.

Key Facts

  • Former employee Wendy Cunning sued Skye Bioscience alleging whistleblower protection violations under Sarbanes-Oxley and California retaliation law.
  • Lawsuit related to actions during the employee's tenure from March 2018 to July 2019.
  • Complaint sought unspecified economic and non-economic losses plus attorneys' fees.
  • On November 10, 2026, after a retrial, the jury returned a unanimous verdict in favor of the company on all claims.
  • Plaintiff may file post-trial motions and may appeal any judgment entered on the verdict.

Financial Impact

No damages awarded; the company prevailed on all claims. The complaint sought unspecified losses, so no quantifiable exposure remains.

Risk Factors

  • Plaintiff may file post-trial motions or appeal, potentially reviving the case.
  • Legal costs incurred in defense, though not disclosed, are now a sunk cost.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-073120
Document: 0001628280-26-073120-index-headers.html0001628280-26-073120
Document: 0001628280-26-073120-index.html0001628280-26-073120
Document: 0001628280-26-073120.txt0001628280-26-073120

Track record

16 reports on SKYE

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Viewing Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026